Experimental trials of predicted CD4⁺ and CD8⁺ T-cell epitopes of respiratory syncytial virus.

ABSTRACT:

Background

Respiratory syncytial virus (RSV) is the most common cause of viral lower respiratory tract infections (LRTIs) in young children around the world and an important cause of LRTI in the elderly. The available treatments and FDA-approved vaccines for RSV only lessen the severity of the infection and are recommended for infants and elderly people.

Methods

We focused on developing a broad-spectrum vaccine that activates the immune system to directly combat RSV. The objective of this study is to identify CD4⁺ and CD8⁺ T-cell epitopes using an immunoinformatics approach to develop RSV vaccines. The efficacy of these peptides was validated through in-vitro and in-vivo studies involving healthy and diseased animal models.

Results

SUBMITTER: Qousain Naqvi ST 

PROVIDER: S-EPMC11018974 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature